Skip to main content
Journal cover image

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.

Publication ,  Journal Article
Doll, D; Goutsou, M; Graziano, S; Ellerton, J; Bitran, J; Modeas, C; Herndon, J; Perry, M; Green, M
Published in: Cancer Chemother Pharmacol
1991

Between July 2, 1987, and August 21, 1987, Cancer and Leukemia Group B (CALGB) conducted a phase II evaluation of carboplatin (CBDCA) and vinblastine (VBL) in advanced non-small-cell lung cancer. Of the 58 patients who entered the study, 55 were eligible and produced follow-up data. Chemotherapy, which was carried out in 28-day cycles, consisted of 4 mg/m2 VBL given on days 1 and 3 and 125 mg/m2 CBDCA given on days 1-3. Partial responses were observed in 10 cases (18%), and 1 patient (2%) exhibited regression of evaluable disease. No complete responses were achieved. The overall objective response rate was 20%. The median survival was 6.1 months, and the median time to treatment failure was 3.3 months. Life-threatening (grade 4) toxicity was mainly leukopenia (20%), followed by anemia (7%), infection (4%), thrombocytopenia (2%), fever (2%), nausea and vomiting (2%), and weight loss (2%). There were two deaths due to infection. The results of this study demonstrate that the combination CBDCA/VBL is active in advanced NSCLC; however, whether this combination is more active than either CBDCA or VBL alone is unknown.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1991

Volume

29

Issue

1

Start / End Page

71 / 74

Location

Germany

Related Subject Headings

  • Vinblastine
  • Time Factors
  • Survival Analysis
  • Remission Induction
  • Oncology & Carcinogenesis
  • Lung Neoplasms
  • Infusions, Intravenous
  • Humans
  • Drug Evaluation
  • Confidence Intervals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Doll, D., Goutsou, M., Graziano, S., Ellerton, J., Bitran, J., Modeas, C., … Green, M. (1991). Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemother Pharmacol, 29(1), 71–74. https://doi.org/10.1007/BF00686339
Doll, D., M. Goutsou, S. Graziano, J. Ellerton, J. Bitran, C. Modeas, J. Herndon, M. Perry, and M. Green. “Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.Cancer Chemother Pharmacol 29, no. 1 (1991): 71–74. https://doi.org/10.1007/BF00686339.
Doll D, Goutsou M, Graziano S, Ellerton J, Bitran J, Modeas C, et al. Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemother Pharmacol. 1991;29(1):71–4.
Doll, D., et al. “Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.Cancer Chemother Pharmacol, vol. 29, no. 1, 1991, pp. 71–74. Pubmed, doi:10.1007/BF00686339.
Doll D, Goutsou M, Graziano S, Ellerton J, Bitran J, Modeas C, Herndon J, Perry M, Green M. Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemother Pharmacol. 1991;29(1):71–74.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1991

Volume

29

Issue

1

Start / End Page

71 / 74

Location

Germany

Related Subject Headings

  • Vinblastine
  • Time Factors
  • Survival Analysis
  • Remission Induction
  • Oncology & Carcinogenesis
  • Lung Neoplasms
  • Infusions, Intravenous
  • Humans
  • Drug Evaluation
  • Confidence Intervals